drugset / Trial / NCT04842331

PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)

NCT04842331

Phase 2/3 Withdrawn Thirty Respiratory Limited
RandomizedParallel-groupOpen-labelPrevention

Summary

This is an open label controlled household-randomised trial designed to evaluate the efficacy of RESP301 alongside standard of care ("SOC") versus SOC alone.

Timeline

Start
2021-09
Primary completion
2022-01
Completion
2022-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Mannitol Diagnostic / imaging agent Inhaled
Subject Sodium Nitrite Small molecule Inhaled
Subject citric acid Unknown Inhaled